INBX
Inhibrx Biosciences, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$910.75M
P/E Ratio
—
EPS
$-9.04
Beta
—
52W High
$94.56
52W Low
$10.80
50-Day MA
$73.41
200-Day MA
$53.87
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Inhibrx Biosciences, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
Fundamentals
| Revenue (TTM) | $1.30M |
| Gross Profit (TTM) | $-111.73M |
| EBITDA | $-132.54M |
| Operating Margin | -10387.00% |
| Return on Equity | -197.80% |
| Return on Assets | -51.60% |
| Revenue/Share (TTM) | $0.08 |
| Book Value | $0.55 |
| Price-to-Book | 115.92 |
| Price-to-Sales (TTM) | 700.58 |
| EV/Revenue | 699.47 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $14.61M |
| Float | $7.81M |
| % Insiders | 26.95% |
| % Institutions | 84.29% |
Data last updated: 4/8/2026